Rare disease leadership CANbridge is a China-focused biopharma with a recognized leadership position in orphan diseases, presenting clear opportunities to partner with global or regional players seeking China market access and commercialization expertise.

Strategic partnerships Key collaborations include a global WuXi Biologics partnership and exclusive rights to Hunterase in greater China, indicating a strong ecosystem for co-development and distribution that can be leveraged to expand product portfolios.

Strong market launches Recent launches of Hunterase and Livmarli in China and the first Gaucher disease prescription for Gaurunning demonstrate active commercial execution and a rapid channel for introducing rare-disease therapies to clinicians and patients.

Pipeline expansion Active efforts in gene therapy (StitchR collaboration), dystrophinopathies programs, and CAN108/LIVMARLI NDA activity signal multiple near-term selling opportunities across rare diseases and potentially transformative technologies.

Regional focus with China access With exclusive rights and a China-centric strategy, CANbridge offers partners access to the Chinese market through established regulatory, distribution, and payer pathways, ideal for companies seeking a strong gateway into Greater China.